INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement of Phase 2 CELIA study results for diranersen (BIIB080), an Alzheimer's disease treatment. Although Biogen described the results as 'compelling,' the study missed its primary dose-response endpoint, causing the stock to fall $13.16 per share (6.43%) to $191.37 on May 14, 2026.